In Reply: 2023 Update in ambulatory general internal medicine
Cleveland Clinic Journal of Medicine · 2024
DOI: 10.3949/ccjm.91c.03002 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cleveland Clinic Journal of Medicine, 2024. Verfasst von Jason T Alexander und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Chicago, Chicago, IL. Hauptthemen laut MEDLINE: Internal Medicine, Ambulatory Care.
Abstract (Originalsprache)
We appreciate Ashley Lim’s close read of our review. Regarding the use of SGLT-2 inhibitors in patients without albuminuria, as we point out, the EMPA-KIDNEY trial[1][1] was the first large randomized trial of SGLT-2 inhibitors to enroll patients with chronic kidney disease without albuminuria.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Medicine, University of Chicago, Chicago, IL.
- Department of Medicine, Case Western Reserve University, Cleveland, OH.
- Department of Medicine, University of Wisconsin, Madison, WI.
Zitieren
APA
Alexander, J. T., Singh, S. K., Shah, S. D., Lambert, B., & Smith, J. P. (2024). In Reply: 2023 Update in ambulatory general internal medicine. Cleveland Clinic Journal of Medicine. https://doi.org/10.3949/ccjm.91c.03002
Vancouver
Alexander JT, Singh SK, Shah SD, Lambert B, Smith JP. In Reply: 2023 Update in ambulatory general internal medicine. Cleveland Clinic Journal of Medicine. 2024. doi:10.3949/ccjm.91c.03002
BibTeX
@article{Alexander2024,
author = {Alexander, Jason T and Singh, Simran K and Shah, Sachin D and Lambert, Brianna and Smith, Jeremy P},
title = {In Reply: 2023 Update in ambulatory general internal medicine},
journal = {Cleveland Clinic Journal of Medicine},
year = {2024},
doi = {10.3949/ccjm.91c.03002}
}
EUVIMED